腾盛博药-B（02137）今日盘中大跌，跌幅高达13.99%，引发市场关注。截至盘中某时刻，该股报2.52港元，成交额1683.76万港元。
消息面上，腾盛博药近日公布的2024年业绩报告显示，公司全年亏损额为5.12亿元，同比大幅扩大177.9%。值得注意的是，公司目前暂无产品实现商业化，其他收入为1.41亿元，同比减少13.6%，主要来源于银行利息和政府补助。
腾盛博药曾在2021年成功研发出国内首个获批的自主知识产权新冠病毒中和抗体联合治疗药物——安巴韦单抗/罗米司韦单抗联合疗法。然而，这款药物在实现商业化后仅8个月便宣布停产，根据2022年年报披露的财务数据，该药物仅为公司带来5160万元收入。目前，公司缺乏可持续的收入来源，这可能是导致投资者信心下降、股价大跌的主要原因。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.